4-[2-[[5-methyl-1-(2-naphtalenyl)-1Hpyrazol-3-yl]oxy]ethyl]morpholine salts

Details for Australian Patent Application No. 2010323116 (hide)

Owner LABORATORIOS DEL DR. ESTEVE, S.A.

Inventors Cuberes-Altisent, Maria Rosa; Sola - Carandell, Lluis; Garcia - Couceiro, Urko

Agent Collison & Co

Pub. Number AU-A-2010323116

PCT Pub. Number WO2011/064315

Priority 09382261.7 25.11.09 EP; 10382025.4 04.02.10 EP

Filing date 25 November 2010

Wipo publication date 3 June 2011

International Classifications

C07D 231/22 Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

A61K 9/16 Medicinal preparations characterised by special physical form - Agglomerates

A61K 31/4152 - having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone

A61P 25/00 Drugs for disorders of the nervous system

Event Publications

21 June 2012 PCT application entered the National Phase

  PCT publication WO2011/064315 Priority application(s): WO2011/064315

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010323117-Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion

2010323104-Sialochimeric compounds